[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340733-105":59,"doc-detail-340733-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fdg-petmri-in-colorectal-cancer-care-an-updated-systematic-review","FDG-PET/MRI in colorectal cancer care - an updated systematic review","","FDG-PET/MRI is advocated as an adjunct in colorectal cancer care since its introduction in 2011, yet existing studies show gaps and limitations in evidence. This updated systematic review evaluates the current literature from 2000 to 2023 to quantify the utility of FDG-PET/MRI. Primary outcomes assess accuracy for initial staging, restaging, and metastatic detection in rectal and colon cancers, while secondary outcomes compare performance versus standard of care imaging and measure clinical impact on management changes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fdg-petmri-in-colorectal-cancer-care-an-updated-systematic-review/340733/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fdg-petmri-in-colorectal-cancer-care-an-updated-systematic-review/340733.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is FDG-PET/MRI considered in colorectal cancer care?","Question",{"text":112,"@type":113},"FDG-PET/MRI has been advocated as a useful adjunct because it combines metabolic information from PET with anatomic and functional capabilities of MRI, potentially improving staging accuracy and influencing management decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What imaging comparisons were evaluated in the review?",{"text":117,"@type":113},"The review compared FDG-PET/MRI performance against standard of care imaging, including MRI pelvis for rectal cancer and thoraco-abdominal contrast CT for broader metastatic assessment.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings about diagnostic performance and management impact?",{"text":121,"@type":113},"Across 22 observational studies (988 patients), FDG-PET/MRI showed superiority for detecting distant metastatic disease versus standard of care imaging, leading to up to a 21.0% change in management. Technological limitations were also noted.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340733,1790197391,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Abdominal Radiology (2025) 50:49–63  \n[https://doi.org/10.1007/s00261-024-04460-z](https://doi.org/10.1007/s00261-024-04460-z)  \nFDG‑PET/MRI in colorectal cancer care: an updated systematic review  \nHui Zhen Lo1 · Kay Tai Choy2 · Joseph Cherng Huei Kong3,4,5,6,7  \nReceived: 23 April 2024 / Revised: 11 June 2024 / Accepted: 15 June 2024 / Published online: 29 July 2024 © Crown 2024  \nAbstract  \nPurpose Since its introduction in 2011, FDG-PET/MRI has been advocated as a useful adjunct in colorectal cancer care. However, gaps and limitations in current research remain. This systematic review aims to review the current literature to quantify the utility of FDG-PET/MRI in colorectal cancer care.  \nMethods An up-to-date review was performed on the available literature between 2000 and 2023 on PubMed, EMBASE, Medline, databases. All studies reporting on the use of FDG-PET/MRI in colorectal cancer care were analyzed. The main outcome measures were accuracy in initial staging, restaging, and detection of metastatic disease in both rectal as well as colon cancers. The secondary outcome was comparing the performance of FDG-PET/MRI versus Standard of Care Imaging (SCI) . Finally, the clinical significance of FDG-PET/MRI was measured in the change in management resulting from imaging findings.  \nResults A total of 22 observational studies were included, accounting for 988 patients. When individually compared to current Standard of Care Imaging (SCI)—MRI pelvis for rectal cancer and thoraco-abdominal contrast CT, PET/MRI proved superior in terms of distant metastatic disease detection. This led to as much as 21.0% change in management. However, the technological limitations of PET/MRI were once again highlighted, suggesting SCI should retain its place as first-line imaging.  \nConclusion FDG-PET/MRI appears to be a promising adjunct in staging and restaging of colorectal cancer in carefully selected patients.  \nGraphical Abstract  \nHui Zhen Lo and Kay Tai Choy are co-first authors and have contributed to this study equally.  \nExtended author information available on the last page of the article  \nKeywords FDG-PET/MRI · Colorectal cancer · Accuracy · Standard of care imaging  \nIntroduction  \nIn the management of colorectal cancer, it is vital to obtain an accurate Tumor, Node and Metastasis (TNM) staging to allow for an individualized treatment approach [1, 2] . This aids in complex discussion particularly in locally advanced rectal cancer (LARC) for which clear oncological margins (distal and circumferential resection margin) is paramount. The routine pre-operative work-up (Standard of Care Imaging) for newly diagnosed colorectal cancer patients include computed tomography (CT) to ensure no distant metastasis, magnetic resonance imaging (MRI) for those with mid to low rectal cancers and additionally [ 18F] Fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT if thereis concern for any occult residual disease that has not been identified by the first two modalities.  \nCurrently, the treatment algorithm for mid to low rectal cancer is evolving [3] . Historically, any patients with LARC, defined as T3-4 with or without nodal positivity, will either receive neoadjuvant short-course radiotherapy or long-course chemoradiotherapy. However, in the last 2 years, there has been increasing interest in Total Neoadjuvant Therapy (TNT): giving induction (before radiotherapy) or consolidation (after radiotherapy) chemotherapy before definitive curative radical surgery [4, 5] . The basis for this intensified regimen is to bring forward neoadjuvant chemotherapy as patients have higher functional reserves and would better tolerate chemotherapy before major surgery. This would hypothetically reduce the risk of distant recurrence.  \nRecent intermediate oncological data has shown improvement in 3-year disease-free survival, with an absolute reduction of approximately 7% when chemotherapy was given before surgery compared to after surgery [5 , 6] . Most i","cbCailXwwqCbqU31","https://ap.wps.com/l/cbCailXwwqCbqU31","pdf",1968458,15,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why is FDG-PET/MRI considered in colorectal cancer care?\",\"answer\":\"FDG-PET/MRI has been advocated as a useful adjunct because it combines metabolic information from PET with anatomic and functional capabilities of MRI, potentially improving staging accuracy and influencing management decisions.\"},{\"question\":\"What imaging comparisons were evaluated in the review?\",\"answer\":\"The review compared FDG-PET/MRI performance against standard of care imaging, including MRI pelvis for rectal cancer and thoraco-abdominal contrast CT for broader metastatic assessment.\"},{\"question\":\"What were the main findings about diagnostic performance and management impact?\",\"answer\":\"Across 22 observational studies (988 patients), FDG-PET/MRI showed superiority for detecting distant metastatic disease versus standard of care imaging, leading to up to a 21.0% change in management. Technological limitations were also noted.\"}]","FDG-PET/MRI in colorectal cancer care - an updated systematic review | PDF",1790038541,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cdb4cfc6e8f25a61f2f5e9a39c729ab.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a44bb23925aca92f06a7df4e61fb148b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/807f7c5ce014ff2f0e0aa1486b673382.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceb840a672063dbd250b897d360fb78a.webp",980,1301]